Higher dose radiation with hormone therapy for high-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a higher dose of radiation given in fewer sessions (hypofractionated) combined with hormone therapy for men with high-risk prostate cancer that has not spread. A gel spacer called SpaceOAR is used to protect the rectum. The goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of prostate adenocarcinoma (a type of prostate cancer) within the last 6 months.
- Your cancer must be high-risk: it has spread outside the prostate (T3a-T4), or has a high Gleason grade (4 or 5), or your PSA level was above 20 ng/mL.
- You are currently receiving or plan to receive hormone therapy for your prostate cancer.
- You are at least 20 years old and in good physical condition (ECOG score 0 or 1, meaning you can do daily activities without help).
- You must agree to have a SpaceOAR procedure (a gel spacer placed between the prostate and rectum to protect the rectum during radiation).
- You cannot have had prior surgery in the lower pelvis (like prostate removal or rectal cancer surgery), prior pelvic radiation, or cancer that has spread to lymph nodes or other organs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a higher dose of radiation in fewer sessions, while using SpaceOAR to protect the rectum, is safe for men with low-to-intermediate risk prostate cancer that hasn't spread.
This trial tests whether giving a higher dose of radiation therapy (called SBRT) can safely and effectively treat high-risk prostate cancer that hasn't spread. It's for men who have not yet been treated for their cancer.
This study looks at combining stereotactic body radiation therapy (a precise type of radiation) with hormone therapy for men with high-risk prostate cancer that hasn't spread. The goal is to see how well this treatment works with fewer side effects.
This trial studies whether giving a moderate “boost” dose of radiation to the prostate—along with radiation to the pelvic area—can better control high-risk localized prostate cancer. You may benefit if you have high-risk disease and can safely receive radiation.
This trial tests whether giving an extra, focused dose of radiation to the visible tumor inside the prostate can improve results for men with intermediate or high-risk prostate cancer that has not spread. The total treatment is given in 12 or 20 sessions.
This trial studies giving hormone treatment and radiation before prostate surgery to treat high-risk, locally advanced prostate cancer. It aims to improve cancer control by shrinking or controlling the tumor before removing it.
Hear when a new High Risk Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.